Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

melphalan hydrochloride

(MEL-fuh-lan HY-droh-KLOR-ide)
A drug used to treat certain types of multiple myeloma and uveal melanoma (a type of eye cancer). An infusion of one form of melphalan hydrochloride is used as palliative therapy to treat multiple myeloma in patients who cannot take melphalan by mouth. Other forms of melphalan hydrochloride are used under the brand name Evomela to prepare patients with multiple myeloma for a stem cell transplant and under the brand name Hepzato to treat adults with uveal melanoma that has spread to less than half of the liver and cannot be removed by surgery. Hepzato is given as an infusion directly into an artery that leads to the liver. Melphalan hydrochloride is also being studied in the treatment of other types of cancer. It may kill cancer cells by damaging their DNA and stopping them from dividing. Melphalan hydrochloride is a type of alkylating agent.
More Information
Search NCI's Dictionary of Cancer Terms